Published in Curr Opin Mol Ther on December 01, 2002
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol (2009) 3.59
Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur Urol (2008) 2.06
Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res (2006) 1.52
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. J Urol (2003) 1.33
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int (2005) 1.27
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol (2010) 1.24
Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol (2004) 1.03
Outcome analysis of fornix ruptures in 162 consecutive patients. J Endourol (2010) 1.02
Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol (2002) 0.93
Destruction of stone extraction basket during an in vitro lithotripsy--a comparison of four lithotripters. J Endourol (2011) 0.93
Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study. Radiother Oncol (2013) 0.91
Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem (2007) 0.91
Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer (2003) 0.90
Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol (2013) 0.89
Prostate cancer vaccines: current status and future potential. BioDrugs (2008) 0.86
Giant bladder diverticulum as a rare cause of intestinal obstruction: report of a case. Surg Today (2007) 0.86
Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res (2005) 0.85
The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma. J Cancer Res Clin Oncol (2009) 0.84
First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. 1981. J Urol (2002) 0.83
Laparoscopic adrenalectomy in urological centres - the experience of the German Laparoscopic Working Group. BJU Int (2011) 0.82
Drug evaluation: Degarelix--a potential new therapy for prostate cancer. IDrugs (2006) 0.82
Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int (2005) 0.82
mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep (2011) 0.82
The use of cryopreserved mature and immature testicular spermatozoa for intracytoplasmic sperm injection: risks and limitations. Semin Reprod Med (2002) 0.81
Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol (2008) 0.80
Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther (2005) 0.80
Degarelix for prostate cancer. Expert Opin Investig Drugs (2009) 0.79
Does adjuvant vitespen prevent recurrence in patients with locally advanced kidney cancer? Nat Clin Pract Urol (2008) 0.77
Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine. Curr Opin Mol Ther (2007) 0.77
Cytokine and vaccine therapy of kidney cancer. Expert Rev Anticancer Ther (2004) 0.77
Degarelix and its therapeutic potential in the treatment of prostate cancer. Clin Interv Aging (2009) 0.77
In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer. In Vivo (2009) 0.77
Could titanium oxide coating from a sol-gel process make stone baskets more resistant to laser radiation at 2.1 μm? J Negat Results Biomed (2012) 0.75
[Editorial comment on Stepp H. et al.: fluorescence diagnosis and photodynamic therapy in urology]. Aktuelle Urol (2007) 0.75
Damage of stone baskets by endourologic lithotripters: a laboratory study of 5 lithotripters and 4 basket types. Adv Urol (2013) 0.75
Results of secondary ureteral implantation after kidney transplantation. Int Urol Nephrol (2011) 0.75
Comparison between a 1.92-μm fiber laser and a standard HF-dissection device for nephron-sparing kidney resection in a porcine in vivo study. Lasers Med Sci (2011) 0.75
Stone/tissue differentiation during intracorporeal lithotripsy using diffuse white light reflectance spectroscopy: In vitro and clinical measurements. Lasers Surg Med (2014) 0.75
Technology evaluation: PROSTVAC, Therion. Curr Opin Mol Ther (2002) 0.75
Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. Expert Rev Anticancer Ther (2006) 0.75
Investigation of bladder deformability within the development process of the artificial urinary diversion system - a pilot study. Int J Artif Organs (2011) 0.75
First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. 1981. J Urol (2002) 0.75
The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette-Guérin and interleukin 2-activated killer cells. Urol Res (2002) 0.75
Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder. Urology (2006) 0.75